Hemophilia A is caused by pathogenic variants in the F8 gene, which encodes coagulation factor VIII, a critical cofactor in the intrinsic coagulation cascade. This causal relationship carries a DEFINITIVE ClinGen validity classification. F8 is located on the X chromosome, producing an X-linked inheritance pattern: hemizygous affected males inherit one pathogenic allele on their single X chromosome; heterozygous females may manifest symptoms as documented in the recognized subtype 'symptomatic form of hemophilia A in female carriers.' Factor VIII deficiency impairs the amplification step of the coagulation cascade, resulting in inadequate thrombus formation and the bleeding phenotype. ClinVar data documents pathogenic variants of multiple types in F8, including deletions and single nucleotide variants. The total pathogenic and likely pathogenic variant count in the current dataset is three, with one high-confidence pathogenic call recorded.

Diagnosis of hemophilia A is established through coagulation studies demonstrating reduced factor VIII activity and confirmed by identification of a pathogenic F8 variant on molecular genetic testing. The recognized severity classification—severe (factor VIII activity less than 1% of normal), moderately severe (1–5%), and mild (greater than 5% to 40%)—corresponds to the MONDO severity subtypes for the condition. The X-linked inheritance pattern means a family history of bleeding in male relatives provides relevant diagnostic context. Genetic testing for F8 pathogenic variants supports identification of carrier females in affected families. ClinVar documents pathogenic variants including deletions and single nucleotide variants in F8. As of the time of data collection, ClinicalTrials.gov documents 153 active hemophilia A studies, including natural history research and diagnostic investigations such as a prevalence study of inhibitor development (NCT07791836).

Seven FDA-approved treatments with active market status are documented for hemophilia A. Antihemophilic factor Fc fusion protein (Eloctate), an extended half-life recombinant factor VIII product, received FDA approval in June 2014. Emicizumab (HEMLIBRA), a bispecific antibody that mimics the cofactor function of factor VIII, received FDA approval in November 2017 and is applicable in individuals with and without inhibitors. Antihemophilic factor Fc-VWF-XTEN fusion protein (ALTUVIIIO), an extended half-life recombinant factor VIII product, received FDA approval in February 2023. Valoctocogene roxaparvovec-rvox (Roctavian) received FDA approval as a biologic in June 2023. Three additional non-factor replacement agents received approval in the period 2024–2025: marstacimab-hncq (HYMPAVZI), approved October 2024; concizumab (ALHEMO), approved December 2024; and fitusiran (QFITLIA), approved March 2025. This most recent approval extends the range of rebalancing therapeutic mechanisms available in hemophilia A. Trial intervention data documents gene therapy as an active intervention type in the current clinical trial portfolio.

Hemophilia A is a lifelong condition characterized by a bleeding diathesis requiring ongoing hemostatic management. Disease severity, determined by residual factor VIII activity, is a primary determinant of bleeding frequency, with severe disease associated with spontaneous joint and soft tissue hemorrhages. Repeated joint bleeding contributes to progressive musculoskeletal impact, reflected in the designation of the skeletal system as a primary affected organ in this dataset. The approved treatment landscape now encompasses multiple mechanism classes—extended half-life factor VIII concentrates, a factor VIII-mimicking bispecific antibody, a gene therapy biologic, and rebalancing agents—reflecting the evolving management environment for this condition. GeneReviews expert guidance on hemophilia A natural history and management is available at the NCBI Bookshelf; the current packet does not include extracted GeneReviews clinical content fields. Ongoing research in inhibitor development, long-term outcomes of gene-based approaches, and novel subcutaneous prophylaxis regimens is documented in active clinical trial registries.

The hemophilia A research landscape is highly active. ClinicalTrials.gov documents 153 active studies at the time of data collection. A classified publication database of 684 studies reflects review and meta-analysis literature as the dominant research type (206 reviews), alongside gene therapy publications, biomarker research, and active trial reporting. Gene therapy represents a major research frontier, with an approved gene therapy biologic (Roctavian) and active investigational programs; the trial intervention summary documents gene therapy as an active intervention type. Notable active and recruiting trials include a Phase 3 comparison of NXT007 versus emicizumab prophylaxis (NCT07416604, Hoffmann-La Roche, recruiting through 2032), two Phase 3 studies of a recombinant factor VIII-Fc fusion protein FRSW107 (NCT07663903 and NCT07684898, Hangzhou Gensciences), a Phase 1 first-in-human study of ARD001 (NCT07787091, Arditus, recruiting), and a Phase 3 safety study of activated prothrombin complex concentrate following emicizumab prophylaxis (NCT04563520, Emory University, recruiting). A lentiviral FVIII gene therapy Phase 1 trial (NCT03217032) is listed as not yet recruiting. Orphan drug designations have been granted for additional investigational approaches including an AAV8-based factor VIII gene therapy vector (Gritgen Therapeutics) and autologous blood outgrowth endothelial cells transduced with lentiviral vector for factor VIII restoration (Sernova Corp). Patient organizations active in the hemophilia A community include the World Federation of Hemophilia (wfh.org, maintains a patient registry), the National Bleeding Disorders Foundation (bleeding.org), and the Hemophilia Federation of America (hemophiliafed.org).